کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8723427 | 1589626 | 2018 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Traitement du diabète de type 2. Où en sommes-nous des voies agissant sur le glucagon ?
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Despite numerous studies dating back more than 60 years, showing the key role of glucagon in the pathophysiology of diabetes, especially type 2 diabetes, therapeutic approaches aiming at reducing its effects are still in the making. The new molecules intended at inhibiting the actions of glucagon, glucagon receptor antagonists (Glucagon-RA), have been the subject of recent trials in patients with type 2 diabetes. It is especially the compound LY2409021 which, for the first time, showed a potential of realistic use. This confirms Roger Unger's visionary and persistent five-decade-long hypothesis of a therapeutic approach based on the role of excess glucagon rather than insulin deficiency. Offering the opportunity to expand, perhaps, our pharmacopoeia. However, recently published security data raises doubts about their near market reach.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Médecine des Maladies Métaboliques - Volume 12, Issue 1, February 2018, Pages 16-21
Journal: Médecine des Maladies Métaboliques - Volume 12, Issue 1, February 2018, Pages 16-21
نویسندگان
S. Halimi, J. Girard,